Drugs / 90Y-DOTA-hLL2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01354457 | Nov 2010 → Jun 2016 | acute lymphoblastic leukemia | Nantes University Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00906841 | Oct 2007 → Mar 2016 | large B-cell lymphoma | French Innovative Leukemia Organisation | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 90Y-DOTA-hLL2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00906841 ↗ |
| Known as | (90)Y-DOTA-epratuzumab | “BACKGROUND: Prognosis of patients with relapsed or refractory acute lymphoblastic leukaemia is poor and new treatments are needed. We aimed to assess the feasibility,...” PMID 26687796 ↗ Feb 2015 |
| Known as | 90Y-Epratuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01354457 ↗ |
| Known as | 90Y-hLL2 | “Evaluation of the Efficacy and Tolerance of Fractionated Radio-immunotherapy With 90Y-Epratuzumab (90Y-hLL2) for Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients” NCT01354457 ↗ |
| Known as | epratuzumab tetraxetan | “BACKGROUND: Prognosis of patients with relapsed or refractory acute lymphoblastic leukaemia is poor and new treatments are needed. We aimed to assess the feasibility,...” PMID 26687796 ↗ Feb 2015 |
| Target | CD22 | “using anti-CD22 90Y-epratuzumab tetraxetan as consolidation” PMID 27964867 ↗ Dec 2016 |